Direct comparison
P-Value vs Alpha: Differences & Decision Rules
Compare p-value vs alpha in hypothesis testing. Contrast preset Type I error thresholds with observed probabilities across scientific research decision rules.
Written and maintained by CASRAI Editorial Board
Last updated
How do P-Value (Observed Significance) and Alpha (Significance Level α) compare side by side?
The table below compares P-Value (Observed Significance) and Alpha (Significance Level α) across 9 dimensions, from core definition & meaning to when to prioritize & apply each.
Side-by-side comparison
| Dimension | P-Value (Observed Significance) | Alpha (Significance Level α) |
|---|---|---|
| Core Definition & Meaning | The conditional probability, calculated under the assumption that the null hypothesis (H₀) and all auxiliary model assumptions are completely true, of obtaining a test statistic at least as extreme as the value observed in the sample data. It ranges continuously from 0 to 1 as an index of data-model incompatibility. A small p-value indicates that the sample data would be unusual if H₀ were true. It does not measure the probability that H₀ is true, nor does it measure the probability that the result occurred by chance alone (Wasserstein & Lazar, 2016). | The pre-specified maximum allowable probability of committing a Type I error—rejecting a true null hypothesis (false positive rate). Expressed as a fixed threshold α ∈ (0, 1), conventionally set at 0.05, 0.01, or 0.005. Alpha serves as a long-run operational performance guarantee across hypothetical repeated identical experiments, ensuring that if H₀ holds universally, no more than 100α% of repeated tests will mistakenly yield a significant verdict (Neyman & Pearson, 1933; NIST Section 7.1.3.1). |
| Timing in the Research Workflow | Calculated strictly post-hoc after data collection, data cleaning, and statistical model execution. The p-value cannot be known prior to experimentation because it depends on sample observations, variance, and the realized test statistic. Evaluating p-values repeatedly during ongoing collection without formal stopping rules constitutes data dredging (p-hacking), which inflates the true Type I error rate. | Established strictly a priori before data collection begins during study design, power analysis, and protocol pre-registration. Alpha must be chosen independently of observed data to prevent confirmation bias and post-hoc threshold adjustment. Pre-specifying alpha is mandatory in confirmatory trials because altering alpha after inspecting sample data invalidates inferential validity (ICH E9 Section 5.5). |
| Theoretical Origin & Statistical Framework | Rooted in Ronald A. Fisher's significance testing framework (Fisher, 1925, 1955). Fisher treated the p-value as a continuous, graded evidentiary measure of discrepancy between sample data and a single null hypothesis (H₀). In Fisherian inference, the p-value is an informal guide to inductive reasoning in an individual experiment, without an explicit mathematical alternative hypothesis. | Rooted in the Neyman-Pearson decision-theoretic framework of hypothesis testing (Neyman & Pearson, 1933). Neyman and Pearson introduced alpha alongside an explicit alternative hypothesis (H₁), defining a behavioral decision rule between competing actions (reject H₀ vs. fail to reject H₀). Alpha controls Type I error while beta (β) controls Type II error, establishing statistical power (1 - β) over repeated sampling. |
| Dependence on Sample Size & Data | Highly sensitive to sample size (N). As sample size increases, standard error decreases, causing the test statistic to rise and the p-value to shrink toward zero for any non-zero effect. In massive datasets, trivial differences yield tiny p-values (p < 0.001). Conversely, in small samples with low power, clinically meaningful effects frequently produce non-significant p-values (e.g., p = 0.08) due to sampling noise (Greenland et al., 2016). | Completely independent of sample data and sample size. Alpha is an invariant decision benchmark set by the investigator or regulatory policy. While alpha does not shift automatically with sample size, researchers use alpha with expected effect size and target power (e.g., 80% or 90%) to determine required sample size before starting. Methodologists recommend justifying alpha based on sample size and error trade-offs (Lakens et al., 2018). |
| Role in Hypothesis Decision Rules | Serves as the observed test quantity compared against alpha. If p ≤ α, the result is declared statistically significant at nominal level α, leading to the rejection of H₀. If p > α, the result is deemed non-significant, failing to reject H₀. In scientific reporting, presenting the exact p-value (e.g., p = 0.027) allows readers to evaluate the continuous degree of evidence rather than relying solely on a binary pass/fail label. | Serves as the decision boundary or cut-off criterion. In sampling distributions, alpha determines the critical values of the test statistic (such as critical z = ±1.96 for a two-tailed test at α = 0.05). These critical values define the rejection region: the tail areas whose combined probability equals alpha. Rejecting H₀ when the test statistic falls in the rejection region is mathematically equivalent to rejecting when p ≤ α (NIST Section 7.1.3.1). |
| Multiplicity & Error Rate Control | Raw unadjusted p-values become inflated across multiple hypothesis tests or subgroup analyses. When conducting 20 independent tests at nominal α = 0.05 under true nulls, the chance of at least one false positive is 1 - (1 - 0.05)²⁰ ≈ 64.2%. Researchers must calculate adjusted p-values (e.g., Bonferroni p_adj = p_raw × k, or Benjamini-Hochberg False Discovery Rate q-values) or compare raw p-values against adjusted alpha thresholds. | Must be partitioned across test families to control the family-wise error rate (FWER ≤ α_family). Multiplicity procedures adjust alpha directly, such as Bonferroni correction (α_per_test = α / k), Holm's step-down procedure, or Dunnett's test. In clinical trials with interim analyses, alpha is allocated across monitoring looks using alpha-spending functions (e.g., O'Brien-Fleming) to preserve overall trial alpha at 0.05 (ICH E9 Section 4.5). |
| Common Interpretive Misconceptions | Common fallacies include believing that the p-value equals the probability that H₀ is true (inverse probability fallacy), that 1 - p equals the probability of replication, that p > 0.05 proves the null hypothesis is true ('absence of evidence is not evidence of absence'), and that a smaller p-value reflects a larger effect size. A p-value alone does not convey effect magnitude or clinical importance (Wasserstein & Lazar, 2016). | A pervasive misconception is believing that setting α = 0.05 ensures that only 5% of published significant findings are false positives. In truth, the false discovery rate (FDR) among positive findings depends on prior odds and statistical power; if true effects are rare, an alpha of 0.05 can yield an empirical false discovery rate exceeding 30% to 50% (Benjamin et al., 2018; Ioannidis, 2005). Another fallacy is treating α = 0.05 as a universal law. |
| Regulatory & Journal Standards | Major biomedical and psychological style manuals (APA 7th edition, ICMJE) mandate reporting exact p-values to two or three decimal places (e.g., p = 0.038, rather than p < 0.05), reserving inequalities for extreme tails (e.g., p < 0.001). Regulators (FDA, EMA) require that p-values never be presented in isolation, but always alongside point estimates of effect size and 95% confidence intervals. | Regulatory authorities (US FDA, EMA) enforce formal standards for alpha in pivotal confirmatory trials. The standard benchmark is two-sided α = 0.05 (or one-sided α = 0.025) for each primary efficacy endpoint. Trials using adaptive designs or group sequential monitoring must provide formal mathematical proof that overall Type I error is strictly bounded by alpha across all stages (ICH E9 Section 5.5). |
| When to Prioritize & Apply Each | Prioritize the p-value during post-experimental data analysis and reporting. Report exact p-values to communicate the observed degree of compatibility between sample data and the null model, contextualizing findings alongside effect sizes, study limitations, and biological plausibility. Avoid using p-values as rigid automated decision filters in exploratory research. | Prioritize alpha during prospective study design, protocol development, and pre-registration. Use alpha to set acceptable false positive risk, calculate required sample size and statistical power, specify multiplicity adjustments, and establish formal stopping rules. Alpha provides the essential benchmark for confirmatory testing where a definitive operational decision is required. |
Sources
- NIST/SEMATECH e-Handbook of Statistical Methods, Section 7.1.3.1 (https://www.itl.nist.gov/div898/handbook/prc/section1/prc131.htm)
- Wasserstein & Lazar (2016), The ASA Statement on p-Values, The American Statistician 70(2):129-133 (https://www.amstat.org/asa/files/pdfs/P-ValueStatement.pdf)
- Greenland et al. (2016), Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations, Eur J Epidemiol 31(4):337-350 (https://pmc.ncbi.nlm.nih.gov/articles/PMC4877414/)
- ICH E9 Harmonised Tripartite Guideline, Statistical Principles for Clinical Trials (https://database.ich.org/sites/default/files/E9_Guideline.pdf)
- Benjamin et al. (2018), Redefine statistical significance, Nature Human Behaviour 2:6-10 (https://www.nature.com/articles/s41562-017-0189-z)
- Lakens et al. (2018), Justify your alpha, Nature Human Behaviour 2:168-171 (https://www.nature.com/articles/s41562-018-0311-x)
Ask CASRAI · free to try
Ask about P-Value vs Alpha: Differences & Decision Rules
2 free questions a day, no account.
An AI assistant for research: funder rules, compliance, methods and publishing. It links the sources behind its answers and labels answers that come from a web search.
Answers draw on CASRAI's guides and dictionary plus the federal and funder documents we index: Federal Register, Grants.gov, Regulations.gov and UKRI.
Works on this site and inside Claude, Cursor and the AI tools you already use.
Everything CASRAI publishes — this page, the dictionary, the guides and the news — stays open to read, with no account and no card.
Common questions
Common questions about P-Value (Observed Significance) vs Alpha (Significance Level α)
What is the primary difference between a p-value and alpha?
+
The primary difference lies in their timing and conceptual role. Alpha (α) is an a priori threshold selected before data collection that defines the maximum acceptable risk of a Type I error (false positive). The p-value is an empirical probability calculated from sample data after the experiment, reflecting the compatibility of observed data with the null hypothesis. Alpha is a fixed decision standard, whereas the p-value is a sample-dependent random variable.
Why must alpha be chosen before calculating the p-value?
+
Alpha must be established before data collection to ensure objectivity and preserve the nominal error rate of the test. If an investigator examines a calculated p-value of 0.06 and subsequently raises alpha from 0.05 to 0.10 to declare significance, the mathematical guarantee of Type I error control is destroyed. Pre-specifying alpha in registered protocols prevents outcome-dependent threshold shifting.
Does a p-value less than alpha prove that the null hypothesis is false?
+
No. A p-value less than or equal to alpha (p ≤ α) indicates only that the observed data are sufficiently unusual under the null hypothesis model to warrant its rejection under a pre-specified decision rule. It does not prove that H₀ is false or that H₁ is true. Even in sound studies, an alpha risk of false rejection remains, and model assumption violations can also produce small p-values.
Does a p-value greater than alpha prove that there is no effect?
+
No. A p-value exceeding alpha (p > α) indicates only that the sample data do not provide sufficient statistical evidence to reject the null hypothesis at the chosen significance level. It never proves that the null hypothesis is true. Non-significance frequently arises when a true effect exists but the study lacked statistical power (e.g., small sample size or high noise) to detect it. Absence of evidence is not evidence of absence.
Can alpha be adjusted or justified rather than defaulting to 0.05?
+
Yes. While alpha = 0.05 is the traditional convention, contemporary methodology emphasizes justifying chosen alpha levels based on sample size, statistical power, prior probabilities, and the relative costs of Type I versus Type II errors (Lakens et al., 2018). High-dimensional fields like genomics adjust alpha to 5 × 10⁻⁸ to control genome-wide false discoveries, while particle physics uses a 5-sigma standard (alpha ≈ 3 × 10⁻⁷).
How does sample size affect the p-value compared to alpha?
+
Sample size directly affects the p-value but does not change alpha. In large samples, standard errors shrink, allowing even trivial differences to yield very small p-values (e.g., p < 0.001). In small samples, clinically meaningful effects often produce p-values above alpha due to large sampling error. Alpha remains an invariant decision benchmark set independently of sample size.
How do p-values and alpha relate to critical values and rejection regions?
+
Critical values and p-values represent two mathematically equivalent routes to the same hypothesis decision. Alpha defines the area of the rejection region in the tails of the test statistic's sampling distribution, establishing the critical values (e.g., z_crit = ±1.96 for two-tailed α = 0.05). A test statistic falls into the rejection region if and only if the calculated p-value is less than or equal to alpha (p ≤ α).
Why do scientific journals and regulatory agencies require reporting exact p-values?
+
Reporting exact p-values (e.g., p = 0.038 rather than p < 0.05) provides full transparency, enabling meta-analysts and readers to gauge the continuous degree of evidence. Dichotomous reporting obscures borderline findings and promotes binary thinking. Regulatory guidelines (such as ICH E9) mandate exact p-values presented alongside effect size point estimates and 95% confidence intervals.
Data: Significance Thresholds, Alpha Standards, and P-Value Reporting across Scientific Domains
A comparative synthesis of pre-specified alpha thresholds, multiplicity correction standards, and p-value reporting requirements across major scientific and regulatory frameworks, compiled from published agency guidelines and consensus methodological literature.
Period covered: 1998/2026. Coverage: International.
| Domain or Regulatory Framework | Standard Alpha Level (α) (probability) | Multiplicity & Interim Control | P-Value Reporting Requirement | Primary Benchmark Reference |
|---|---|---|---|---|
| Confirmatory Drug Trials (US FDA / ICH E9) | 0.05 | Formal alpha-spending functions (O'Brien-Fleming or Pocock) for interim monitoring; strict FWER control across co-primary endpoints | Exact p-values required alongside point estimates and 95% confidence intervals for all primary efficacy measures | ICH E9 Harmonised Guideline (database.ich.org) |
| Behavioral & Social Science Discoveries (Benjamin et al. 2018) | 0.005 | Pre-registered analysis plans with family-wise error or false discovery rate adjustments; 0.005 to 0.05 deemed suggestive | Exact p-values reported with Bayes factor bounds and effect size estimates with standard errors | Nature Human Behaviour (doi:10.1038/s41562-017-0189-z) |
| Epidemiological & Observational Studies (Greenland et al. 2016) | 0.05 | Exploratory multiplicity adjustments; rigid thresholding discouraged in favor of continuous estimation | Exact p-values reported continuously; dichotomous claims of significance discouraged in favor of confidence intervals | Eur J Epidemiol / PMC4877414 (2016) |
| Genome-Wide Association Studies (GWAS / NHGRI Standards) | 5e-8 | Genome-wide Bonferroni correction adjusting for approximately one million independent linkage disequilibrium blocks | Exact p-values reported with Manhattan plots and mandatory independent replication cohort validation | NHGRI GWAS Catalog & Consensus Methodology |
| Physical Sciences & Particle Physics (CERN / LHC 5-Sigma Standard) | 3e-7 | Look-elsewhere effect (LEE) trials factor corrections applied across all analyzed energy mass bins | Sigma significance levels and exact p-values reported for discovery claims (5-sigma requires p | Particle Data Group (PDG) Review on Statistics |
| Engineering & Physical Metrology (NIST/SEMATECH e-Handbook) | 0.05 | Rejection regions established per test distribution; alpha adjusted based on operational failure risk | Exact p-values compared against critical values or pre-selected alpha thresholds | NIST e-Handbook Section 7.1.3.1 (itl.nist.gov) |
| General Statistical Practice Consensus (ASA 2016 Statement) | 0.05 | Full transparency and contextual evaluation; automated default reliance on 0.05 rejected | Exact p-values reported in full context; never treated as isolated proof of effect or hypothesis truth | The American Statistician 70(2):129-133 (2016) |
Sources
- ICH E9 Statistical Principles for Clinical Trials (accessed 2026-11-15)
- Redefine Statistical Significance (Benjamin et al. 2018) (accessed 2026-11-15)
- Statistical tests, P values, confidence intervals, and power (Greenland et al. 2016) (accessed 2026-11-15)
- NIST/SEMATECH e-Handbook of Statistical Methods: Critical values and p values (accessed 2026-11-15)
- The ASA Statement on p-Values (Wasserstein & Lazar 2016) (accessed 2026-11-15)
- Justify your alpha (Lakens et al. 2018) (accessed 2026-11-15)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.
Going deeper







